Sophie Schumacher1, Florence Pache1,2, Judith Bellmann-Strobl1,3, Janina Behrens1, Petr Dusek4,2, Lutz Harms5,6, Klemens Ruprecht5,6, Petra Nytrova2, Sanjeev Chawla7, Thoralf Niendorf8,3, Ilya Kister9, Friedemann Paul10,11,12,13, Yulin Ge7, Jens Wuerfel1,4,8,3,14, Tim Sinnecker1,14,15,16. 1. NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany. 2. Department of Neurology and Center of Clinical Neuroscience, 1st Faculty of Medicine, General University Hospital in Prague, Charles University in Prague, Prague, Czech Republic. 3. Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany. 4. Institute of Neuroradiology, Universitätsmedizin Göttingen, Göttingen, Germany. 5. Clinical and Experimental Multiple Sclerosis Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany. 6. Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany. 7. Department of Radiology, NYU School of Medicine, New York, NY, USA. 8. Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine, Berlin, Germany. 9. Department of Neurology, Multiple Sclerosis Care Center, NYU School of Medicine, New York, NY, USA. 10. NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany. friedemann.paul@charite.de. 11. Clinical and Experimental Multiple Sclerosis Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany. friedemann.paul@charite.de. 12. Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany. friedemann.paul@charite.de. 13. Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany. friedemann.paul@charite.de. 14. Medical Image Analysis Center AG (MIAC), Basel, Switzerland. 15. Department of Neurology, Asklepios Fachklinikum Teupitz, Teupitz, Germany. 16. Department of Neurology, Universitätsspital Basel, Basel, Switzerland.
Abstract
OBJECTIVE: To quantify the periventricular venous density in neuromyelitis optica spectrum disease (NMOSD) in comparison to that in patients with multiple sclerosis (MS) and healthy control subjects. MATERIALS AND METHODS: Sixteen patients with NMOSD, 16 patients with MS and 16 healthy control subjects underwent 7.0-Tesla (7T) MRI. The imaging protocol included T2*-weighted (T2*w) fast low angle-shot (FLASH) and fluid-attenuated inversion recovery (FLAIR) sequences. The periventricular venous area (PVA) was manually determined by a blinded investigator in order to estimate the periventricular venous density in a region of interest-based approach. RESULTS: No significant differences in periventricular venous density indicated by PVA were detectable in NMOSD versus healthy controls (p = 0.226). In contrast, PVA was significantly reduced in MS patients compared to healthy controls (p = 0.013). CONCLUSION: Unlike patients with MS, those suffering from NMOSD did not show reduced venous visibility. This finding may underscore primary and secondary pathophysiological differences between these two distinct diseases of the central nervous system.
OBJECTIVE: To quantify the periventricular venous density in neuromyelitis optica spectrum disease (NMOSD) in comparison to that in patients with multiple sclerosis (MS) and healthy control subjects. MATERIALS AND METHODS: Sixteen patients with NMOSD, 16 patients with MS and 16 healthy control subjects underwent 7.0-Tesla (7T) MRI. The imaging protocol included T2*-weighted (T2*w) fast low angle-shot (FLASH) and fluid-attenuated inversion recovery (FLAIR) sequences. The periventricular venous area (PVA) was manually determined by a blinded investigator in order to estimate the periventricular venous density in a region of interest-based approach. RESULTS: No significant differences in periventricular venous density indicated by PVA were detectable in NMOSD versus healthy controls (p = 0.226). In contrast, PVA was significantly reduced in MS patients compared to healthy controls (p = 0.013). CONCLUSION: Unlike patients with MS, those suffering from NMOSD did not show reduced venous visibility. This finding may underscore primary and secondary pathophysiological differences between these two distinct diseases of the central nervous system.
Authors: Ho Jin Kim; Friedemann Paul; Marco A Lana-Peixoto; Silvia Tenembaum; Nasrin Asgari; Jacqueline Palace; Eric C Klawiter; Douglas K Sato; Jérôme de Seze; Jens Wuerfel; Brenda L Banwell; Pablo Villoslada; Albert Saiz; Kazuo Fujihara; Su-Hyun Kim Journal: Neurology Date: 2015-02-18 Impact factor: 9.910
Authors: Stephane Kremer; Felix Renard; Sophie Achard; Marco A Lana-Peixoto; Jacqueline Palace; Nasrin Asgari; Eric C Klawiter; Silvia N Tenembaum; Brenda Banwell; Benjamin M Greenberg; Jeffrey L Bennett; Michael Levy; Pablo Villoslada; Albert Saiz; Kazuo Fujihara; Koon Ho Chan; Sven Schippling; Friedemann Paul; Ho Jin Kim; Jerome de Seze; Jens T Wuerfel; Philippe Cabre; Romain Marignier; Thomas Tedder; Danielle van Pelt; Simon Broadley; Tanuja Chitnis; Dean Wingerchuk; Lekha Pandit; Maria Isabel Leite; Metha Apiwattanakul; Ingo Kleiter; Naraporn Prayoonwiwat; May Han; Kerstin Hellwig; Katja van Herle; Gareth John; D Craig Hooper; Ichiro Nakashima; Douglas Sato; Michael R Yeaman; Emmanuelle Waubant; Scott Zamvil; Olaf Stüve; Orhan Aktas; Terry J Smith; Anu Jacob; Kevin O'Connor Journal: JAMA Neurol Date: 2015-07 Impact factor: 18.302
Authors: Emma C Tallantyre; Paul S Morgan; Jennifer E Dixon; Ali Al-Radaideh; Matthew J Brookes; Nikos Evangelou; Peter G Morris Journal: Invest Radiol Date: 2009-09 Impact factor: 6.016
Authors: Ingo Kleiter; Anna Gahlen; Nadja Borisow; Katrin Fischer; Klaus-Dieter Wernecke; Brigitte Wegner; Kerstin Hellwig; Florence Pache; Klemens Ruprecht; Joachim Havla; Markus Krumbholz; Tania Kümpfel; Orhan Aktas; Hans-Peter Hartung; Marius Ringelstein; Christian Geis; Christoph Kleinschnitz; Achim Berthele; Bernhard Hemmer; Klemens Angstwurm; Jan-Patrick Stellmann; Simon Schuster; Martin Stangel; Florian Lauda; Hayrettin Tumani; Christoph Mayer; Lena Zeltner; Ulf Ziemann; Ralf Linker; Matthias Schwab; Martin Marziniak; Florian Then Bergh; Ulrich Hofstadt-van Oy; Oliver Neuhaus; Alexander Winkelmann; Wael Marouf; Jürgen Faiss; Brigitte Wildemann; Friedemann Paul; Sven Jarius; Corinna Trebst Journal: Ann Neurol Date: 2015-11-26 Impact factor: 10.422
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker Journal: Neurology Date: 2015-06-19 Impact factor: 9.910